Compare QUIK & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QUIK | MSLE |
|---|---|---|
| Founded | 1988 | N/A |
| Country | United States | Canada |
| Employees | 51 | 17 |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.8M | 146.9M |
| IPO Year | 1997 | N/A |
| Metric | QUIK | MSLE |
|---|---|---|
| Price | $16.51 | $7.73 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $11.00 | N/A |
| AVG Volume (30 Days) | ★ 376.6K | 52.0K |
| Earning Date | 05-12-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $20,112,000.00 | N/A |
| Revenue This Year | $75.17 | N/A |
| Revenue Next Year | $16.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.80 | $5.50 |
| 52 Week High | $16.89 | $13.39 |
| Indicator | QUIK | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 73.88 | 51.69 |
| Support Level | $5.67 | $6.73 |
| Resistance Level | N/A | $8.37 |
| Average True Range (ATR) | 1.24 | 0.75 |
| MACD | 0.35 | 0.14 |
| Stochastic Oscillator | 90.67 | 33.83 |
QuickLogic Corp is a fabless semiconductor company developing programmable logic semiconductor technologies, including embedded Field Programmable Gate Array (eFPGA) intellectual property (IP) and specialized FPGA devices. Its product offerings include the eFPGA IP licensing business and associated professional services, as well as a range of FPGA silicon products, including EOS, ArcticLink III, PolarPro 3, PolarPro II, PolarPro, and Eclipse II products, among others. The company's customers come from various markets, including aerospace and defense, industrial and infrastructure systems, data processing and computing platforms, and certain embedded and edge computing applications. Geographically, it generates maximum revenue from North America and the rest from Asia Pacific and Europe.
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.